Company Overview and News

UPL / Ultra Petroleum Corp. 8-K (Current Report)

upl-8k_20180319.htm UNITED STATES

Ultra Petroleum Provides Q1 Production Update, Stock Falls

2018-04-20 zacks
Ultra Petroleum Corp. (UPL - Free Report) recently provided first-quarter 2018 production update along with information regarding its borrowing base credit facility, which is supported by a lender consortium. The company plummeted 8.6% yesterday following the update, which brings it 32% down in the past 30-day period.

BRIEF-Ultra Petroleum Q1 Average Production Of 803 MMcfe/d

2018-04-19 reuters

Ultra Petroleum Announces First Quarter Production Above Mid-Point of Guidance, Borrowing Base Reaffirmed at $1.4 Billion and Credit Agreement Amendment Stepping Up Leverage Ratio Covenant to 4.5X

2018-04-19 globenewswire
During the first quarter of 2018, the Company’s production averaged 803 million cubic feet equivalent (MMcfe) per day, exceeding the mid-point of guidance of 790 to 810 MMcfe/d. Production volumes include 68.2 billion cubic feet of natural gas and 677.8 thousand barrels of oil and condensate and represents a 13% increase over the production volumes of first quarter 2017.

Horizon Pharma (HZNP) Down 3.9% Since Earnings Report: Can It Rebound?

2018-04-02 zacks
A month has gone by since the last earnings report for Horizon Pharma Public Limited Company (HZNP - Free Report) . Shares have lost about 3.9% in that time frame.

Why Is Mylan N.V. (MYL) Up 1.2% Since Its Last Earnings Report?

2018-04-02 zacks
It has been about a month since the last earnings report for Mylan N.V. (MYL - Free Report) . Shares have added about 1.2% in that time frame.

Why Is Analog Devices (ADI) Up 3.2% Since Its Last Earnings Report?

2018-04-02 zacks
A month has gone by since the last earnings report for Analog Devices, Inc. (ADI - Free Report) . Shares have added about 3.2% in that time frame.

Ultra Petroleum (UPL) Up 16.5% Since Earnings Report: Can It Continue?

2018-04-02 zacks
A month has gone by since the last earnings report for Ultra Petroleum Corp. UPL). Shares have added about 16.5% in that time frame.

For Some Wounded US Drillers, the Oil Rout Never Ended

2018-03-27 rigzone
(Bloomberg) -- More than a year after exiting bankruptcy, SandRidge Energy Inc. is stuck in stock-market purgatory.

For some wounded American drillers, the oil rout never ended

2018-03-27 worldoil
The oil and gas explorer has seen its stock sink 37% since October 2016, despite a restructuring that wiped out $4 billion in debt. Activist investor Carl Icahn is threatening a proxy fight, and last week SandRidge rejected a merger that would have valued the once $11-billion company at just $589 million.

UPL / Ultra Petroleum Corp. 424B3 (Prospectus)

424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-217481 PROSPECTUS

New Strong Sell Stocks for March 15th

2018-03-15 zacks
Westinghouse Air Brake Technologies Corporation (WAB - Free Report) is a provider of equipment, systems, and services for the freight rail and passenger transit vehicles. The Zacks Consensus Estimate for its current year earnings has been revised 4.5% downward over the last 30 days.

Is the Options Market Predicting a Spike in Univar (UNVR) Stock?

2018-03-14 zacks
Investors in Univar Inc. (UNVR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 16, 2018 $25.00 Call had some of the highest implied volatility of all equity options today.

Related Articles

TROV: TrovaGene Analysis and Research Report

2m - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics Analysis and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

CUSIP: 903914208